Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Key Inclusion Criteria:

- Eligible individuals will be male and nonpregnant, nonlactating females, aged 18 to 70
years (inclusive), body mass index (BMI) between 18 and 36 kg/m^2 (inclusive), with
either impaired hepatic function or normal hepatic function.

- Individuals will be current nonsmokers (no use of tobacco, nicotine-containing, or
tetrahydrocannabinol (THC)-containing products within the last 14 days).

- Individuals with hepatic impairment will be categorized by the Child-Pugh-Turcotte
(CPT) classification system indicating hepatic impairment as follows:

- Class A (mild): CPT score 5-6

- Class B (moderate): CPT score 7-9

- Class C (severe): CPT score 10-15

- Hepatic impairment must have been stable during the 3 months (90 days) prior to study
drug. Each individual in the control group will be matched to a individual with
impaired hepatic function by age (± 10 years), gender, and body mass index (± 15%).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.